NLRP3-IN-74 (Compound 11) is an orally active NLRP3 inhibitor with an IC50 of 2.7 µM. It significantly reduces IL-1beta release by approximately 90% without affecting TNFalpha release. NLRP3-IN-74 is applicable in research on diseases such as atherosclerosis and Parkinsons disease.
Target:
NOD-like Receptor (NLR)
* VAT and and shipping costs not included. Errors and price changes excepted
